Valeant Pharmaceuticals International (VRX) reported fourth quarter adjusted EPS of $2.50 Tuesday morning, which fell short of the consensus estimate of $2.61. The company also slashed its full year 2016 adjusted EPS forecast to between $9.50 and $10.50, from prior expectations of $13.25 to $13.75. Street expectations are for EPS of $13.24.
from RTT - Before the Bell http://ift.tt/1R2zGxc
via IFTTT
No comments:
Post a Comment